Actively Recruiting
Randomized Trial of Visugromab and Nivolumab With or Without Docetaxel Compared to Docetaxel Alone for Second-Line Treatment of Metastatic Non-Squamous NSCLC
Led by CatalYm GmbH · Updated on 2026-10-26
131
Participants Needed
36
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the anti-GDF-15 antibody Visugromab in combination with Nivolumab and Docetaxel for participants with metastatic non-squamous non-small cell lung cancer NSCLC who have not responded to prior first-line treatment including a checkpoint inhibitor. This phase 2b, randomized, placebo-controlled, and double-blinded trial aims to find signals of effectiveness and safety across different dose levels and treatment combinations. The study includes three parts an open-label safety run-in, followed by a randomized phase with four treatment groups. Participants receive intravenous infusions every 3 weeks of either Visugromab at two dose levels plus Nivolumab with Docetaxel, Visugromab at a higher dose plus Nivolumab with placebo, or double placebo with Docetaxel. After initial treatment of a subset of participants, an interim safety and efficacy analysis is performed before continuing treatment of remaining participants. Participants will be closely monitored with regular assessments over months, including measuring tumor response using Objective Response Rate ORR for up to 36 months, and tracking safety events for up to 60 months. Additional measures include progression-free survival, overall survival, symptom questionnaires, and drug concentrations. This comprehensive follow-up helps researchers understand treatment effects and participant well-being over time.
CONDITIONS
Brief Title
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Research Team
L
Lena Lemke, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here